NDAINTRAVENOUSPOWDER
Approved
Mar 2025
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
3/8 — Basic
GOZELLIX (gozetotide) by Innovation Pharmaceuticals is 68 gozetotide binds to psma. First approved in 2025.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GOZELLIX (gozetotide) is a gallium-68 positron emission tomography (PET) imaging agent that binds to prostate-specific membrane antigen (PSMA) expressed on prostate cancer cells. It is administered intravenously as a powder formulation and enables diagnostic visualization of PSMA-positive malignancies, primarily prostate cancer. The β+ emitting radionuclide gallium-68 allows real-time PET imaging to detect and localize disease.
Growth9.1 years to LOE
Early-stage growth asset with no established competitive pressure; commercial team will focus on physician adoption and diagnostic uptake in oncology centers.
Mechanism of Action
68 gozetotide binds to PSMA. It binds to cells that express PSMA, including malignant prostate cancer cells, which usually overexpress PSMA. Gallium-68 is a β+ emitting radionuclide that allows positron emission tomography.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
GOZELLIX represents a rare early-stage oncology diagnostic launch with minimal current job postings, indicating company is still ramping commercial infrastructure. Joining the team now offers ground-floor opportunity to shape brand positioning in an emerging imaging market with strong patent protection and no immediate competitive threats.
Brand Manager
Worked on GOZELLIX at Innovation Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.